Lung non-cellule cancer early stage specific self antibody panel diagnostic kit

A technology for non-small cell carcinoma and non-small cell lung cancer, applied in biological testing, material inspection products, measuring devices, etc., can solve the problem of insufficient sensitivity and specificity to meet lung cancer screening, and achieve high diagnostic value and operability Effects of Simplicity, Sensitivity, and Specificity Improvement

Active Publication Date: 2018-07-27
QIANFOSHAN HOSPITAL OF SHANDONG
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, the study found that the sensitivity and specificity of a single marker is not enough for lung cancer scree

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lung non-cellule cancer early stage specific self antibody panel diagnostic kit
  • Lung non-cellule cancer early stage specific self antibody panel diagnostic kit
  • Lung non-cellule cancer early stage specific self antibody panel diagnostic kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Preliminary screening experiment:

[0048] Serum collection: The serum of the control group came from healthy people in the physical examination center. All lung cancer cases have been diagnosed by histopathology, according to the latest WHO classification of lung cancer and the 6th UICC staging standard for lung cancer, and meet the following requirements: ①Patients with primary lung non-small cell carcinoma (including squamous cell carcinoma) confirmed by histopathology or cytology cell carcinoma (squamous cell carcinoma), adenocarcinoma, large cell carcinoma). ②Have not received any anti-cancer treatment before blood collection. ③ All patients signed the informed consent.

[0049] First, the patient's serum was hybridized with a chip containing 1627 disease-related proteins to obtain specific binding highlights. The chip was scanned by MicroVigene software (Vigene Tech version 2.9.9.2) to obtain the optical density value. The antigenic protein specifically...

Embodiment 2

[0055] Example 2 Medium screening experiment scheme:

[0056] 1) Serum collection: Serum from patients with benign lung tumors: ① No anti-cancer treatment was received before blood collection. ② All patients signed the informed consent. The inclusion criteria for all lung cancer cases were the same as the initial screening.

[0057] 2) Screening in the protein chip: Print the antigenic proteins corresponding to the 10 initially screened antibodies on glass slides to make chips, add patient serum or control serum to each chip, add rabbit anti-human secondary antibody, scan, Statistical analysis.

[0058] The basis for screening autoantibodies is: on the premise that the specificity is greater than 90%, the sensitivity is above 20%.

[0059] The 6 autoantibodies were HOXA1, IKZF3, KLF8, NF2, POU4F3, and TLX2 obtained through intermediate screening.

[0060] Conclusion: In the screening experiment, the above 6 autoantibodies were obtained after statistical analysis.

Embodiment 3

[0061] Embodiment 3 Verification stage experimental scheme:

[0062] 1) Serum collection: The principle of collection is the same as that of the primary screening stage. But there can be no repeat serum.

[0063] 2) Use ELISA (enzyme-linked immunosorbent assay) method to detect the relative expression level (OD value) of the effective antibody obtained after screening. The method is as follows: in a 96-well plate, after incubation overnight with the antibody coated with anti-GST, the corresponding antigenic protein with the GST label is added, and the antigen is captured by the anti-GST and coated in the well plate. Then add experimental serum to incubate, finally add rabbit anti-human secondary antibody, TMB substrate color development, OD450 reading value.

[0064] Basis for screening autoantibodies: under the premise that the specificity is greater than 90%, the sensitivity is above 30%.

[0065] Conclusion: The specific autoantibodies NF2, KLF8 and POU4F3 in three sera ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a lung non-cellule cancer early stage specific self antibody panel diagnostic kit, which is prepared from antigen generating NF2, KLF8 and POU4F3 antibodies, a 1M sodium bicarbonate buffer solution, a PBST buffer solution, enzyme labelled antibodies, TMB substrates and a termination solution. The kit has the advantages that the sensitivity is high; the specificity is high;the operation is simple; the detection is convenient; when the kit is popularized in clinics, certain significance is realized on the diagnosis of the lung non-cellule cancer.

Description

technical field [0001] The invention relates to the technical field of medical detection reagents, in particular to a specific early autoantibody ELISA panel for non-small cell carcinoma of the lung. Background technique [0002] Lung cancer has become the first cause of death of malignant tumors in urban population in my country, and the 5-year survival rate is 30-40%. Lung cancer generally refers to malignant tumors originating from the bronchial mucosal epithelium. According to the pathological analysis of the World Health Organization (WHO), lung cancer can be divided into two main tissue types: small cell lung cancer (SCLC, small cell lung cancer) and non-small cell lung cancer (NSCLC, non-small cell lung cancer). [0003] Non-small cell lung cancer includes squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, its cancer cells grow and divide more slowly, and spread and metastasize relatively l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
CPCG01N33/6854
Inventor 杜娟
Owner QIANFOSHAN HOSPITAL OF SHANDONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap